Suchergebnisse - "Vitale, Candida"

PubPharm (92)

1

Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines

enthalten in: Blood reviews | 2024

von Mikulska, M. | Oltolini, C. | Zappulo, E. | +5

2

Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment : A multicenter SEIFEM study

enthalten in: American journal of hematology | 2024

von Autore, F. | Visentin, A. | Deodato, M. | +21

3

What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study

enthalten in: Cancers | 2024

von D'Arena, G. | Vitale, C. | Pietrantuono, G. | +15

4

Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment : A multicenter SEIFEM study

enthalten in: American Journal of Hematology | 2024

von Autore, F. | Visentin, A. | Deodato, M. | +21

5

CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia : Is the Uphill Road Getting Less Steep?

enthalten in: HemaSphere | 2023

von Vitale, C. | Griggio, V. | Perutelli, F. | +1

6

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study

enthalten in: Hematological oncology | 2023

von Autore, F. | Innocenti, I. | Reda, G. | +28

7

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia

enthalten in: Scientific reports | 2023

von Vitale, C. | Griggio, V. | Todaro, M. | +11

8

Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia : A chronic lymphocytic leukemia campus study

enthalten in: American journal of hematology | 2023

von Visentin, A. | Mauro, F. | Scarfò, L. | +27

9

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile : results of the GIMEMA phase II LLC1518 - VERITAS study

enthalten in: Haematologica | 2023

von Mauro, F. | Starza, I. | Messina, M. | +44

CommentIn: Haematologica. 2023 Aug 01;108(8):1975-1978. - PMID 36815386

10

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL : Two-Year Follow-Up of a Multicenter Study

enthalten in: Cancers | 2023

von Mauro, F. | Giannarelli, D. | Galluzzo, C. | +21

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]